DENTSPLY SIRONA Inc. $XRAY Shares Purchased by Private Management Group Inc.

Key Points

• Private Management Group increased its DENTSPLY SIRONA stake by 47.4% in the second quarter, purchasing 794,107 additional shares for a total holding of 2.47 million shares valued at $26.2 million.
• Institutional investors and hedge funds own 95.7% of XRAY, with several firms—including BlackRock, Edmond de Rothschild, and Paradigm Capital—establishing or expanding positions.
• Analysts maintain a consensus “Hold” rating with a $13.54 target price. The company recently beat quarterly EPS estimates ($0.52 versus $0.35) but reported a 4.1% year-over-year revenue decline and a negative net margin.

Private Management Group Inc. increased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 47.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,470,726 shares of the medical instruments supplier's stock after buying an additional 794,107 shares during the quarter. Private Management Group Inc. owned 1.24% of DENTSPLY SIRONA worth $26,214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its stake in shares of DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier's stock worth $167,342,000 after acquiring an additional 458,744 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new position in shares of DENTSPLY SIRONA in the 2nd quarter valued at approximately $47,780,000. Paradigm Capital Management Inc. NY purchased a new position in shares of DENTSPLY SIRONA in the 2nd quarter valued at approximately $39,775,000. BlackRock Inc. acquired a new stake in DENTSPLY SIRONA in the 2nd quarter worth approximately $283,405,000. Finally, UBS Group AG boosted its stake in DENTSPLY SIRONA by 63.7% in the 4th quarter. UBS Group AG now owns 1,701,980 shares of the medical instruments supplier's stock worth $19,454,000 after purchasing an additional 662,000 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on XRAY. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Piper Sandler raised their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a "neutral" rating in a report on Wednesday, July 29th. BMO Capital Markets reiterated a "market perform" rating and set a $13.00 price objective on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Barclays boosted their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an "underweight" rating in a report on Monday, August 24th. Finally, Barrington Research set a $15.00 target price on DENTSPLY SIRONA in a research report on Monday, August 10th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $13.54.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Zacks Research increased its FY2026 EPS estimate to $1.50 from $1.41, above the current consensus estimate of $1.41. This is the clearest supportive factor for DENTSPLY SIRONA (XRAY) today.
• Neutral Sentiment: Zacks maintained estimates of $1.50 EPS for FY2027 and $1.64 EPS for FY2028 in its updated forecast set, providing some stability despite reductions to individual periods.
• Negative Sentiment: The firm lowered its Q3 2026 EPS estimate to $0.31 from $0.37 and cut Q4 2026 EPS to $0.40 from $0.41. The Q3 revision is particularly notable because it represents a larger reduction in expected near-term profitability.
• Negative Sentiment: Additional cuts included Q2 2027 EPS to $0.38 from $0.39, Q3 2027 EPS to $0.41 from $0.42, Q4 2027 EPS to $0.39 from $0.40, Q1 2028 EPS to $0.35 from $0.37, Q2 2028 EPS to $0.41 from $0.42, and FY2028 EPS to $1.64 from $1.65.

DENTSPLY SIRONA Trading Up 0.7%

Shares of NASDAQ:XRAY opened at $11.12 on Friday. DENTSPLY SIRONA Inc. has a 12-month low of $9.40 and a 12-month high of $14.86. The company has a market capitalization of $2.22 billion, a PE ratio of -4.04, a PEG ratio of 1.39 and a beta of 0.85. The business has a 50 day moving average of $12.10 and a two-hundred day moving average of $11.75. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million for the quarter, compared to analysts' expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business's revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the company earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts forecast that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current year.

Insider Activity at DENTSPLY SIRONA

In other news, Director Michael J. Barber acquired 15,175 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the transaction, the director owned 55,943 shares in the company, valued at approximately $552,716.84. The trade was a 37.22% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian P. Mckeon bought 10,000 shares of the stock in a transaction dated Friday, June 12th. The shares were purchased at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the purchase, the director owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 35,160 shares of company stock worth $351,179. 0.46% of the stock is owned by company insiders.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source